Specifically, CD4+ T, CD8+ T, and B cells have been linked to enhanced clinical outcomes, whereas regulatory cell types, such as regulatory T cells and neutrophils, have been associated with poorer outcomes in ovarian cancers [22]. This evidence concerns the gene CD4 and ovarian cancer.